Thymopoietic Platform
Immune reconstitution in aging, cancer, immune-compromised settings
Pre-clinicalActive
Key Facts
Indication
Immune reconstitution in aging, cancer, immune-compromised settings
Phase
Pre-clinical
Status
Active
Company
About TECregen
TECregen is a private, pre-clinical stage biotech pioneering a novel therapeutic class aimed at regenerating the thymus to restore immune function. The company leverages a proprietary platform combining expertise in thymus biology, immunology, and synthetic cytokine engineering to develop next-generation, targeted thymopoietic proteins. With a recent CHF 10 million seed financing round and the appointment of a seasoned drug development veteran as CEO, TECregen is positioning its platform for advancement into clinical development. Its mission is to address the significant unmet medical need in immune senescence, oncology supportive care, and immune reconstitution.
View full company profile